Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety

Hepatology

Volumn 51, Issue 1, 2010, Pages 165-173

  Vitale, Alessandro ^a   Volk, Michael L ^b   Pastorelli, Davide ^a   Lonardi, Sara ^a   Farinati, Fabio ^c   Burra, Patrizia ^c   Angeli, Paolo ^c   Cillo, Umberto ^c  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE;

BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; HUMANS; LIVER TRANSPLANTATION; MARKOV CHAINS; MODELS, THEORETICAL; MONTE CARLO METHOD; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; WAITING LISTS;

EID: 73449094529     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23260     Document Type: Article

References (27)

1. Harper AM, Edwards EB, Eleison MD. The OPTN waiting list, 1988-2000. Clin Transplant 2001;73-85.
2. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. HEPATOLOGY 1999;30:1434-1440.
3. Freeman RB Jr. The model for end-stage liver disease comes of age. Clin Liver Dis 2007;11:249-263.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
5. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma. Analysis of survival according to the intention-to-treat principle, and drop-out from the waiting list. Liver Transpl 2002;8:873-883.
6. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver disease. Am J Transpl 2006;6:1416-1421.
7. Graziadei IW, Sandmueller H, Waldenberger P, Koenigrsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563.
8. Lu DSK, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HEPATOLOGY 2005;41:1130-1137.
9. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003;238:885-892; discussion 892-893.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42:1208-1236.
11. Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transpl 2007;7:1875-1881.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
13. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
14. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
15. United Network for Organ Sharing/Organ Procurement and Transplantation Network. UNOS/OPTN policy 3.6.4.4. http://optn.transplant. hrsa.gov/. Accessed September 2009.
16. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18:S68-S80.
17. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684-692.
18. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-128.
19. Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. HEPATOLOGY 2000;31:899-906.
20. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. HEPATOLOGY 2001;33:1073-1079.
21. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transpl 2008;8:839-846.
22. Volk M, Lok ASF, Vijan S. Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation. Med Decis Making 2008;28:763-772
23. Bruix J, Raoul JL, Sherman M, Shan M, Lentini G, Nadel A, et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of Sharp trial based on Barcelona Clinic Liver Cancer (BCLC) stage [Abstract]. J Hepatol 2009;50(Suppl 1):S28. Abstract 67.
24. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
25. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. HEPATOLOGY 2008;48:1312-1327.
26. Schrag D. The price tag on progress- chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-319.
27. Tappended P, Jones R, Paisley S, Carrol C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:12.